Last reviewed · How we verify
EFV plus ABC/3TC or RPV/TDF/FTC
This is a combination antiretroviral regimen that inhibits HIV reverse transcriptase and integrase to suppress viral replication.
This is a combination antiretroviral regimen that inhibits HIV reverse transcriptase and integrase to suppress viral replication. Used for HIV-1 infection treatment.
At a glance
| Generic name | EFV plus ABC/3TC or RPV/TDF/FTC |
|---|---|
| Also known as | NNRTI-Based Regimens |
| Sponsor | Juan A. Arnaiz |
| Drug class | Antiretroviral combination therapy (NNRTI + NRTIs) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
EFV (efavirenz) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase. The regimen is paired with either ABC/3TC (abacavir/lamivudine) or RPV/TDF/FTC (rilpivirine/tenofovir/emtricitabine), which are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs). Together, these agents suppress HIV replication by blocking the reverse transcriptase enzyme required for viral reproduction.
Approved indications
- HIV-1 infection treatment
Common side effects
- Neuropsychiatric effects (dizziness, impaired concentration, abnormal dreams)
- Rash
- Nausea
- Hepatotoxicity
- Lipid elevation
- Lactic acidosis (rare)
Key clinical trials
- Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (PHASE3)
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
- Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I (PHASE3)
- Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC (PHASE3)
- Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EFV plus ABC/3TC or RPV/TDF/FTC CI brief — competitive landscape report
- EFV plus ABC/3TC or RPV/TDF/FTC updates RSS · CI watch RSS
- Juan A. Arnaiz portfolio CI